215 related articles for article (PubMed ID: 19144715)
1. MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival.
Forte E; Luftig MA
J Virol; 2009 Mar; 83(6):2491-9. PubMed ID: 19144715
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation.
Price AM; Tourigny JP; Forte E; Salinas RE; Dave SS; Luftig MA
J Virol; 2012 Oct; 86(20):11096-106. PubMed ID: 22855490
[TBL] [Abstract][Full Text] [Related]
3. EBV latency III immortalization program sensitizes B cells to induction of CD95-mediated apoptosis via LMP1: role of NF-kappaB, STAT1, and p53.
Le Clorennec C; Youlyouz-Marfak I; Adriaenssens E; Coll J; Bornkamm GW; Feuillard J
Blood; 2006 Mar; 107(5):2070-8. PubMed ID: 16317104
[TBL] [Abstract][Full Text] [Related]
4. Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells.
Renouf B; Hollville E; Pujals A; Tétaud C; Garibal J; Wiels J
Leukemia; 2009 Sep; 23(9):1557-63. PubMed ID: 19421231
[TBL] [Abstract][Full Text] [Related]
5. An EBV recombinant deleted for residues 130-159 in EBNA3C can deregulate p53/Mdm2 and Cyclin D1/CDK6 which results in apoptosis and reduced cell proliferation.
Shukla SK; Jha HC; El-Naccache DW; Robertson ES
Oncotarget; 2016 Apr; 7(14):18116-34. PubMed ID: 26908453
[TBL] [Abstract][Full Text] [Related]
6. The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells.
Forte E; Salinas RE; Chang C; Zhou T; Linnstaedt SD; Gottwein E; Jacobs C; Jima D; Li QJ; Dave SS; Luftig MA
J Virol; 2012 Jun; 86(12):6889-98. PubMed ID: 22496226
[TBL] [Abstract][Full Text] [Related]
7. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells.
Cahir-McFarland ED; Carter K; Rosenwald A; Giltnane JM; Henrickson SE; Staudt LM; Kieff E
J Virol; 2004 Apr; 78(8):4108-19. PubMed ID: 15047827
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors.
Ma Y; Walsh MJ; Bernhardt K; Ashbaugh CW; Trudeau SJ; Ashbaugh IY; Jiang S; Jiang C; Zhao B; Root DE; Doench JG; Gewurz BE
Cell Host Microbe; 2017 May; 21(5):580-591.e7. PubMed ID: 28494239
[TBL] [Abstract][Full Text] [Related]
9. An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation.
Kaye KM; Izumi KM; Li H; Johannsen E; Davidson D; Longnecker R; Kieff E
J Virol; 1999 Dec; 73(12):10525-30. PubMed ID: 10559372
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus infection and mitogen stimulation of normal B cells induces wild-type p53 without subsequent growth arrest or apoptosis.
Pokrovskaja K; Okan I; Kashuba E; L Wbeer M; Klein G; Szekely L
J Gen Virol; 1999 Apr; 80 ( Pt 4)():987-995. PubMed ID: 10211969
[TBL] [Abstract][Full Text] [Related]
11. c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.
Faumont N; Durand-Panteix S; Schlee M; Grömminger S; Schuhmacher M; Hölzel M; Laux G; Mailhammer R; Rosenwald A; Staudt LM; Bornkamm GW; Feuillard J
J Virol; 2009 May; 83(10):5014-27. PubMed ID: 19264782
[TBL] [Abstract][Full Text] [Related]
12. Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis.
Pujals A; Renouf B; Robert A; Chelouah S; Hollville E; Wiels J
Cell Death Dis; 2011 Jul; 2(7):e184. PubMed ID: 21796156
[TBL] [Abstract][Full Text] [Related]
13. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of Dual-Specificity Phosphatases by Epstein-Barr Virus LMP1 and Its Impact on Lymphoblastoid Cell Line Survival.
Lin KM; Lin SJ; Lin JH; Lin PY; Teng PL; Wu HE; Yeh TH; Wang YP; Chen MR; Tsai CH
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776277
[TBL] [Abstract][Full Text] [Related]
15. Tumor Suppressor p53 Stimulates the Expression of Epstein-Barr Virus Latent Membrane Protein 1.
Wang Q; Lingel A; Geiser V; Kwapnoski Z; Zhang L
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794023
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53.
Allday MJ; Sinclair A; Parker G; Crawford DH; Farrell PJ
EMBO J; 1995 Apr; 14(7):1382-91. PubMed ID: 7729416
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.
Lai KY; Chou YC; Lin JH; Liu Y; Lin KM; Doong SL; Chen MR; Yeh TH; Lin SJ; Tsai CH
J Virol; 2015 Jun; 89(11):5968-80. PubMed ID: 25810549
[TBL] [Abstract][Full Text] [Related]
18. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
Price AM; Messinger JE; Luftig MA
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
[TBL] [Abstract][Full Text] [Related]
19. Dynamic Epstein-Barr virus gene expression on the path to B-cell transformation.
Price AM; Luftig MA
Adv Virus Res; 2014; 88():279-313. PubMed ID: 24373315
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr Virus Induces Adhesion Receptor CD226 (DNAM-1) Expression during Primary B-Cell Transformation into Lymphoblastoid Cell Lines.
Grossman L; Chang C; Dai J; Nikitin PA; Jima DD; Dave SS; Luftig MA
mSphere; 2017; 2(6):. PubMed ID: 29202043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]